Drugs / funapide
funapide
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04826328 | Mar 2021 → Jan 2022 | toe, misshapen | Pacira Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT02215941 | Aug → Nov 2014 | — | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01486446 | Dec 2011 → Apr 2012 | primary erythermalgia | Xenon Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 23 trials · 2 missed | ||||||
| Phase 2 | NCT02365636 | Feb 2015 → May 2017 | postherpetic neuralgia | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | Missed primary |
| Phase 2 | NCT02068599 | Apr 2014 → Apr 2015 | osteoarthritis, knee | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | Missed primary |
| Phase 2 | NCT01195636 | Aug 2010 → Mar 2011 | postherpetic neuralgia | Xenon Pharmaceuticals Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2017-06-27 | Teva Branded Pharmaceutical Products R&D, Inc. | Results Teva and Xenon Announce Phase II Study of Topical TV-45070 in Patients with Post-Herpetic Neuralgia (PHN) Did Not Meet Primary Endpoint tevapharm.com ↗
TV-45070 did not meet the primary endpoint of a statistically significant change in pain from baseline to week four as assessed by the numeric rating scale (NRS). |
| 2017-06-27 | Xenon Pharmaceuticals Inc. | Results Teva and Xenon Announce Phase II Study of Topical TV-45070 in Patients with Post-Herpetic Neuralgia (PHN) Did Not Meet Primary Endpoint xenon-pharma.com ↗
TV-45070 did not meet the primary endpoint of a statistically significant change in pain from baseline to week four as assessed by the numeric rating scale (NRS). |
| 2015-07-01 | Teva Branded Pharmaceutical Products R&D, Inc. | Results Teva and Xenon Provide Update on TV-45070 Phase 2b Study in Osteoarthritis Pain tevapharm.com ↗
Results from this trial showed that TV-45070 4% and 8% did not demonstrate statistically significant difference from placebo in efficacy endpoints of reductions in pain due to OA. |
| 2015-07-01 | Xenon Pharmaceuticals Inc. | Results Teva and Xenon Provide Update on TV-45070 Phase 2b Study in Osteoarthritis Pain xenon-pharma.com ↗
Results from this trial showed that TV-45070 4% and 8% did not demonstrate statistically significant difference from placebo in efficacy endpoints of reductions in pain due to OA. |
| 2013-04-23 | Xenon Pharmaceuticals Inc. | Regulatory Teva and Xenon Announce FDA Orphan Drug Designation for Pain Drug XEN402 xenon-pharma.com ↗
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Xenon Pharmaceuticals Inc. (Xenon) announced today that the US Food and Drug Administration (FDA) has granted orphan-drug designation to the investigational drug XEN402 being developed for the treatment of pain associated with erythromelalgia (EM). |
| 2011-05-02 | Xenon Pharmaceuticals Inc. | Results Xenon’s XEN402 Ointment Significantly Relieves Pain in Patients with Post Herpetic Neuralgia xenon-pharma.com ↗
Xenon Pharmaceuticals Inc. (Xenon) announced today that its novel ointment XEN402 demonstrated significant and clinically meaningful reductions in pain in patients with Post Herpetic Neuralgia (PHN). |
All press releases naming this drug 15 releases
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | funapide | “FX301 is an extended-release formulation of funapide being developed as a single injection peripheral nerve block for the management of acute postsurgical pain” NCT04826328 ↗ |
| Known as | Funapida | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707218 ↗ |
| Known as | FX301 | “FX301 is an extended-release formulation of funapide being developed as a single injection peripheral nerve block for the management of acute postsurgical pain” NCT04826328 ↗ |
| Known as | TV-45070 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02068599 ↗ |
| Known as | XEN-401-S | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707218 ↗ |
| Known as | XEN402 | “Topically Applied XPF-002 (XEN402 8% w/w Ointment)” NCT01486446 ↗ |
| Known as | XPF-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01195636 ↗ |
| Action | Inhibit | “a topical semiselective sodium 1.7 channel (Nav1.7) blocker” PMID 37366590 ↗ Jun 2023 |
| Modality | Small molecule | — CHEMBL3707218 ↗ |
| Route | Topical | “Twice daily application of XPF-002 ointment” NCT01195636 ↗ |